Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Hypoactive Sexual Desire Disorder

In brief

The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

Key facts

Study ID
NCT03287232
Run by
EndoCeutics Inc.
People needed
653
Starts
2017-10-16
Expected to finish
2019-07-22
Last updated by the study team
2021-04-09

Who can join

Age: 40 and older, up to 80. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.